Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 9078–9079.

https://doi.org/10.1182/blood-2022-167349

Published: 2022

Journal Articles

A Novel Lair-1 Antibody Selectively Targets Acute Myeloid Leukemia (AML) Stem Cells

Linjie Tian, Ana Paucarmayta, Rustin Lovewell, Karla Maloveste, Junshik Hong, Carly Hedgepath, Kwang Woon Kim, Ron Copeland, Thomas O'Neill, Shashank Patel, Linda N. Liu, Han Myint, Solomon Langermann, Dallas B Flies, Tae Kon Kim

Blood (2021) 138 (Supplement 1): 3413.

https://doi.org/10.1182/blood-2021-147656

Published: 2021

Journal Articles

Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses

Monzr M. Al Malki, MD, Miguel-Angel Perales, MD, Dipenkumar Modi, MD, Sumithira Vasu, MDMBBS, Megan Nelson, RN, Donna Bui, Sojung Kim, Ruipeng Wang, Emily Lu, Mathias Oelke, Han Myint, MDFRCPath,FRCP, Juan C. Varela, MDPhD

Blood (2020) 136 (Supplement 1): 31–33.

https://doi.org/10.1182/blood-2020-139342

Published: 2020

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

Journal Articles

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

Srdan Verstovsek, MD, PhD, James P. Dean, MD, PhD, Paul Cernohous, MS, Rami S Komrokji, MD, John F. Seymour, MBBS, FRACP, PhD, Ruben A. Mesa, MD, Mary S Campbell, MD, Susan E. Caldwell, PhD, Lixia Wang, PhD, Han Myint, MD

Blood (2013) 122 (21): 395.

https://doi.org/10.1182/blood.V122.21.395.395

Published: 2013

Journal Articles

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Scott Smith, MD, PhD, FACP, John E. Godwin, MD, MS, Ralph Boccia, MD, Han Myint, MD, Daruka Mahadevan, MD, PhD, Deborah Mulford, MD, Mark Rarick, MD, Mary Ann Allison, MD, Ostap Melnyk, MD, Lisa Meng, Marsha Jones, MD, Gail Brown, MD, Shelby A Young, RN, BSN, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 2910.

https://doi.org/10.1182/blood.V116.21.2910.2910

Published: 2010

Journal Articles

An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide.

Choon Kee Lee, MD, Jeff Kaiser, Pharm., D., Han Myint, FRCP, FRCPath, Mary Berg, MD, J. Fred Kolhouse, MD, William Robinson, MD

Blood (2009) 114 (22): 3404.

https://doi.org/10.1182/blood.V114.22.3404.3404

Published: 2009

Journal Articles

Presence of Dysregulated Immune Recovery (IMD) Following Autotransplant May Change the Type of Predominant Serum Light Chain and Elevate the Level in Patients with Multiple Myeloma (MM).

Choon Kee Lee, MD, Mary Berg, MD, John Ryder, Han Myint, FRCP, FRCPath, J. Fred Kolhouse, MD, William Robinson, MD

Blood (2009) 114 (22): 4870.

https://doi.org/10.1182/blood.V114.22.4870.4870

Published: 2009

Journal Articles

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

Andres Forero-Torres, MD, Nancy L Bartlett, MD, Sunita D Nasta, MD, Donald Northfelt, MD, Anne Beaven, MD, Han Myint, FRCP, FRCPath, Nancy C Whiting, PharmD, BCOP, Jonathan G Drachman, MD, Craig H Moskowitz, MD

Blood (2009) 114 (22): 586.

https://doi.org/10.1182/blood.V114.22.586.586

Published: 2009

Journal Articles

Unremitting Presence of Marrow Immunoglobulin Heavy Chain Gene Rearrangement (IGH-GR) 3 Months Following Autotransplant Is Associated with Poor Outcome in Disease Control in Patients with Multiple Myeloma (MM).

Choon Kee Lee, MD, Qi Wei, Director, Laboratory, Develpment, Molecular, Diagnostics, Mark Lovell, Associate, Professor, Karen Swisshelm, Co-Director, John Ryder, Han Myint, FRCP, FRCPath, J. Fred Kolhouse, MD, William Robinson, MD

Blood (2009) 114 (22): 1807.

https://doi.org/10.1182/blood.V114.22.1807.1807

Published: 2009

Journal Articles

Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma

Robert W. Chen, Lynne T. Bemis, Carol M. Amato, Han Myint, Hung Tran, Diane K. Birks, S. Gail Eckhardt, William A. Robinson

Blood (2008) 112 (3): 822–829.

https://doi.org/10.1182/blood-2008-03-142182

Published: 2008

Journal Articles

Intensive Induction Therapy with Melphalan 50 mg/m 2 (MEL50) for Patients with AL Amyloidosis.

Choon Kee Lee, MD, Han Myint, MD, Peterson J. Glen, ACNP, Kolhouse J. Fred, MD, Hannis W. Thompson, MD

Blood (2007) 110 (11): 5122.

https://doi.org/10.1182/blood.V110.11.5122.5122

Published: 2007

Journal Articles

Treatment of Extranodal Marginal Zone Lymphoma and Primary Cutaneous B Cell Lymphoma with Rituximab: A Single Institution Experience.

Robert Chen, MD, Glen Peterson, NP, Diana Vucurevich, NP, Choon-kee Lee, MD, William Robinson, MD, Han Myint, MD, FRCP

Blood (2007) 110 (11): 4502.

https://doi.org/10.1182/blood.V110.11.4502.4502

Published: 2007

Journal Articles

B-Type Natriuretic Peptide (BNP) and Mitral Velocity E/A Ratio (MV E/A) Are Two Important Noninvasive Functional Indices of Cardiac AL Amyloidosis.

Peter Kabos, MD, Qaiser Bashir, MD, Robert Chen, MD, JoAnn Lindenfeld, MD, Han Myint, MD, Choon Kee Lee, MD

Blood (2007) 110 (11): 4773.

https://doi.org/10.1182/blood.V110.11.4773.4773

Published: 2007

Journal Articles

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

Nicolaus Kröger, Georgia Schilling, Hermann Einsele, Peter Liebisch, Avichai Shimoni, Arnon Nagler, Jose A. Perez-Simon, Jesus F. San Miguel, Michael Kiehl, Axel Fauser, Rainer Schwerdtfeger, Hannes Wandt, Herbert G. Sayer, Han Myint, Hans Klingemann, Tatjana Zabelina, Judith Dierlamm, Axel Hinke, Axel R. Zander

Blood (2004) 103 (11): 4056–4061.

https://doi.org/10.1182/blood-2003-12-4435

Published: 2004

NARROW

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

A Novel Lair-1 Antibody Selectively Targets Acute Myeloid Leukemia (AML) Stem Cells

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide.

Presence of Dysregulated Immune Recovery (IMD) Following Autotransplant May Change the Type of Predominant Serum Light Chain and Elevate the Level in Patients with Multiple Myeloma (MM).

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

Unremitting Presence of Marrow Immunoglobulin Heavy Chain Gene Rearrangement (IGH-GR) 3 Months Following Autotransplant Is Associated with Poor Outcome in Disease Control in Patients with Multiple Myeloma (MM).

Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma

Intensive Induction Therapy with Melphalan 50 mg/m 2 (MEL50) for Patients with AL Amyloidosis.

Treatment of Extranodal Marginal Zone Lymphoma and Primary Cutaneous B Cell Lymphoma with Rituximab: A Single Institution Experience.

B-Type Natriuretic Peptide (BNP) and Mitral Velocity E/A Ratio (MV E/A) Are Two Important Noninvasive Functional Indices of Cardiac AL Amyloidosis.

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only